Since January 2021, Menkes International Association (MIa) has been working to provide elesclomol-copper treatment to Menkes patients worldwide. This groundbreaking treatment, first tested successfully on a young boy named Marco, has brought hope to children suffering from this devastating disease. With the approval of national medical authorities, MIa is coordinating access to elesclomol-copper treatment, and six cases are currently underway.

CORE is the pharma-clinical team of Menkes International that carries out the follow-up of the exceptional treatments of the Menkes patients treated with elesclomol-copper by supporting local medical teams and providing clinical management advice.

Attending Pediatrician, Complex Chronic Children and Palliative Care Unit, Department of Pediatrics, Regional University Hospital, Málaga, Spain (COORDINATOR)

Chair of the Copperless Committee. Pediatrician and Clinical geneticist. Chairman of the Scientific Advisory Board of SJD Únicas and SJD Distinguished Research Fellow

Clinical Researcher, Department of Genetic Medicine and Pediatric Institute of Rare Diseases (IPER and CIBERER), Hospital Sant Joan Déu, Barcelona, Spain

Neurological Physiotherapist, Expert in Menkes children, Dulce Nombre de Maria Psychopedagogic Institute, Málaga

Hospital Pharmacist (Consultant), Hospital Sant Joan de Déu, Barcelona, Spain

Hospital Pharmacist (Consultant), Hospital Sant Joan de Déu, Barcelona, Spain

Hospital Pharmacist, Complejo hospitalario León, Spain

Hospital Pharmacist, Complejo hospitalario León, Spain